LJ570

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: LJ570
• 英文别名: (2s)-3-(Biphenyl-4-Yl)-2-(Biphenyl-4-Yloxy)propanoic Acid；(2S)-2-(4-phenylphenoxy)-3-(4-phenylphenyl)propanoic acid
• 化学式: C₂₇H₂₂O₃
• 分子量: 394.47
• InChiKey: DGMLYRGMJHVKNC-SANMLTNESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (R)-ethyl 4-iodophenyllactate 在 四(三苯基膦)钯 、 偶氮二甲酸二异丙酯 、 caesium carbonate 、 三苯基膦 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 35.0h， 生成 LJ570
  参考文献：
  名称：

  Identification of the First PPARα/γ Dual Agonist Able To Bind to Canonical and Alternative Sites of PPARγ and To Inhibit Its Cdk5-Mediated Phosphorylation

  摘要：

  A new series of derivatives of the PPAR alpha/gamma dual agonist 1 allowed us to identify the ligand (S)-6 as a potent partial agonist of both PPAR alpha and gamma subtypes. X-ray studies in PPAR gamma revealed two different binding modes of (S)-6 to the canonical site. However, (S)-6 was also able to bind an alternative site as demonstrated by transactivation assay in the presence of a canonical PPAR gamma antagonist and supported from docking experiments. This compound did not activate the PPAR gamma-dependent program of adipocyte differentiation inducing a very less severe lipid accumulation compared to rosiglitazone but increased the insulin-stimulated glucose uptake in 3T3-L1 adipocytes. Finally, (S)-6 inhibited the Cdk5-mediated phosphorylation of PPAR gamma at serine 273 that is currently considered the mechanism by which some PPAR gamma partial agonists exert antidiabetic effects similar to thiazolidinediones, without showing their typical side effects. This is the first PPAR alpha/gamma dual agonist reported to show this inhibitory effect representing the potential lead of a new class of drugs for treatment of dyslipidemic type 2 diabetes.

  DOI：

  10.1021/acs.jmedchem.8b00835

文献信息

• <i>para</i>-Selective arylation and alkenylation of monosubstituted arenes using thianthrene <i>S</i>-oxide as a transient mediator
  作者：Xiao-Yue Chen、Xiao-Xue Nie、Yichen Wu、Peng Wang

  DOI：10.1039/d0cc00641f

  日期：——

  Using thianthrene S-oxide (TTSO) as a transient mediator, para-arylation and alkenylation of mono-substituted arenes have been demonstrated via a para-selective thianthrenation/Pd-catalyzed thio-Suzuki-Miyaura coupling sequence under mild conditions. This reaction features a broad substrate scope, and functional group and heterocycle tolerance. The versatility of this approach was further demonstrated

  使用噻吩硫氧化物（TTSO）作为瞬时介体，单取代的芳烃的对位芳构化和烯基化反应已通过在温和条件下通过对位选择性噻吩化/ Pd催化的硫代-Suzuki-Miyaura偶联序列进行。该反应具有广泛的底物范围，官能团和杂环耐受性。复杂的生物活性支架的后期功能化以及一些药物的直接合成，进一步证明了这种方法的多功能性，包括Tetriprofen，Ibuprofen，Bifonazole和LJ570。
• 对位取代芳基化合物的制备方法
  申请人：中国科学院上海有机化学研究所

  公开号：CN111187130B

  公开（公告）日：2021-12-14

  本发明公开了一种如式(I)所示的对位取代芳基化合物的制备方法，其特征在于，包括以下步骤：惰性气氛下，溶剂中，在碱和钯催化剂的作用下，如式(II)所示的芳基锍盐与如式(III)所示的硼化物进行偶联反应，即可。该方法以单取代芳烃为底物，原位构建芳基锍盐，钯催化剂催化原位构建的芳基锍盐发生Suzuki‑Miyaura偶联反应，快速高效构建单取代芳烃对位芳基化或烯基化产物。该方法条件温和，底物普适性高，杂环偶联底物耐受性广泛。
• Identification of the First PPARα/γ Dual Agonist Able To Bind to Canonical and Alternative Sites of PPARγ and To Inhibit Its Cdk5-Mediated Phosphorylation
  作者：Antonio Laghezza、Luca Piemontese、Carmen Cerchia、Roberta Montanari、Davide Capelli、Marco Giudici、Maurizio Crestani、Paolo Tortorella、Franck Peiretti、Giorgio Pochetti、Antonio Lavecchia、Fulvio Loiodice

  DOI：10.1021/acs.jmedchem.8b00835

  日期：2018.9.27

  A new series of derivatives of the PPAR alpha/gamma dual agonist 1 allowed us to identify the ligand (S)-6 as a potent partial agonist of both PPAR alpha and gamma subtypes. X-ray studies in PPAR gamma revealed two different binding modes of (S)-6 to the canonical site. However, (S)-6 was also able to bind an alternative site as demonstrated by transactivation assay in the presence of a canonical PPAR gamma antagonist and supported from docking experiments. This compound did not activate the PPAR gamma-dependent program of adipocyte differentiation inducing a very less severe lipid accumulation compared to rosiglitazone but increased the insulin-stimulated glucose uptake in 3T3-L1 adipocytes. Finally, (S)-6 inhibited the Cdk5-mediated phosphorylation of PPAR gamma at serine 273 that is currently considered the mechanism by which some PPAR gamma partial agonists exert antidiabetic effects similar to thiazolidinediones, without showing their typical side effects. This is the first PPAR alpha/gamma dual agonist reported to show this inhibitory effect representing the potential lead of a new class of drugs for treatment of dyslipidemic type 2 diabetes.